College of Pharmacy Researcher Lands $900,000 Grant for Nail Fungus Study
CINCINNATI
-
Fungal nail disease can be an unsightly, painful and debilitating condition, with the only clinically recognized treatments being oral anti-fungal medicationswhich distribute through the entire bodyor a topical lacquer with a rigid application process and a 30 percent total cure rate.
Nail disease such as onychomycosis is usually not life threatening, but it is a quality of life issue, says UC researcher Kevin Li, PhD, an associate professor at the James L. Winkle College of Pharmacy.
Li is currently investigating methods to deliver medication once a week via gel and low electric current into and across the nail plate. The study is sponsored by a four-year, $900,000 grant from the National Institutes of Health.
According to the American Academy of Dermatology, about 12 percent of Americans suffer from some type of fungal nail disease. The toenails are affected most often because the feet stay in a dark and moist environment.
The fungus is also easily spread in showers or locker rooms. Symptoms can range from discoloration to losing the nail.
Li says, Its not just a matter of appearance. In serious cases, people cant wear shoes or button their clothes.
The problem with the oral medications, he says, is that they can lead to severe side effects such as liver toxicity and cannot be taken by everyone, such as people with low liver function.
You have to flood the whole body just to treat the fungus in and under the nail, he says, and the medicated lacquer has to be applied frequently and on schedule.
Both treatments, he says, also often take months to take effectif at all.
Unfortunately, once nail disease starts it can be persistent and patients dont always have the patience to follow the course of treatmentand even if they do, the fungus can still be resistant.
There is an unmet need for more effective treatment, Li says.
Lis ongoing research interests extend to drug delivery methods involving the skin, eyes and ears.
Other members of the research team working on this study are: professor Jerry Kasting, PhD, research assistant professor Jinsong Hao, PhD, and graduate student Kelly Smith. All are with the James L. Winkle College of Pharmacy.
Tags
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.